The PD-L1 Inhibitor Screening Assay Kit from AMSBIO is designed for screening and profiling inhibitors of this signalling. This kit comes in a convenient 96-well format, with biotin-labelled PD-1, ...

Agilent (A) announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for the use as a Companion Diagnostic to aid in ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

The meta-analysis, published in the August 2019 JAMA Oncology and cited above, focused on four assay types most commonly used in immuno-oncology: tumour mutational burden, PD-L1 IHC, gene ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

Akoya Biosciences (AKYA) announced a collaboration with the Singapore Translational Cancer Consortium on the STCC Unified PD1/PDL1 Evaluation ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as ...